GlassScriptPhysician profile
Laura Esserman
NPI 1679537971
$420.63
in general payments reported to CMS, 2019-2025
14 companies · $68.00 in 2025
The $68.00 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $26.42 · 2024: $19.65 · 2025: $68.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $191.04 | 2019 | |
| Endomagnetics LTD | $115.52 | 2019 | |
| Genentech USA, INC. | $68.00 | 2025 | |
| Seagen INC. | $26.42 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $19.65 | 2024 |
9 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Esserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.